Abstract
Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-Angiogenic Therapy in Renal Cell Carcinoma
Volume: 5 Issue: 1
Author(s): Shree G. Sharma, Sudip Nanda and Santo Longo
Affiliation:
Keywords: Angiogenesis, renal cell carcinoma, VHL, VEGF, sorafenib, sumitinib, bevacizumab, temsirolimus, mTOR, angiopoietins
Abstract: Renal cell carcinoma (RCC) is one of the most common cancers in the United States. Recent achievements in translational research have lead to significant developments in treatment strategies for this malignancy. RCC is a richly vascular neoplasm. A better understanding of its biology has helped in the development of antiangiogenic therapy. Vascular endothelial growth factor (VEGF) is the most important molecular target in the treatment of RCC. Patents have been filed for anti-VEGF and other molecular pathways involved in the pathogenesis of RCC.
Export Options
About this article
Cite this article as:
Sharma G. Shree, Nanda Sudip and Longo Santo, Anti-Angiogenic Therapy in Renal Cell Carcinoma, Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (1) . https://dx.doi.org/10.2174/157489210789702181
DOI https://dx.doi.org/10.2174/157489210789702181 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Use of Radioactive Iodine in the Management of Hyperthyroidism in Children
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Pretreatment Serum Fibrinogen Levels are Associated with Postoperative Distant Metastasis and Prognosis of Resected Lung Cancer Patient: A Retrospective Study
Current Signal Transduction Therapy Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Onco-Surgical Management of Colo-Rectal Liver Metastases in Older Patients: A New Frontier in the 3<sup>rd</sup> Millennium
Anti-Cancer Agents in Medicinal Chemistry Development of Tissue Engineered Vascular Grafts
Current Pharmaceutical Biotechnology Molecular Targeting of Cell Death Signal Transduction Pathways in Cancer
Current Signal Transduction Therapy NK-1 Receptor Antagonists: A New Paradigm in Pharmacological Therapy
Current Medicinal Chemistry Hormone-Biological Therapy in Breast Cancer: Preclinical Evidence,Clinical Studies and Future Directions
Current Cancer Drug Targets Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry Pleural Fluid Analysis for Evaluating Pleural Effusions
Current Respiratory Medicine Reviews Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Recent Advances and Future Directions in the Management of Metastatic Renal Cell Carcinoma
Anti-Cancer Agents in Medicinal Chemistry EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Current Drug Targets uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer
Current Medicinal Chemistry Ultrasound Diagnosis of Soft Tissue Vascular Malformations and Tumours
Current Medical Imaging Clinical Considerations of Focal Drug Delivery in Cancer Treatment
Current Drug Delivery The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis